TYRA-300 is a small molecule commercialized by Tyra Biosciences, with a leading Phase II program in Metastatic Transitional (Urothelial) Tract Cancer. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TYRA-300’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for TYRA-300 is expected to reach an annual total of $131 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

TYRA-300 Overview

Tyra-300 is under development for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract, solid tumors and achondroplasia. The drug candidate acts by targeting fibroblast growth factor (FGF) receptor 3. It is being developed based on SNAP platform. It is administered by oral route.

Tyra Biosciences Overview

Tyra Biosciences (Tyra) is a precision oncology company that design and develop cancer drugs. It is investigating Tyra-300, an FGFR3 (fibroblast growth factor receptor 3) inhibitor targeting bladder and solid tumors. The company evaluates FGFR2 small molecule inhibitor for the treatment of bile duct and solid tumors; FGFR3 (ACH) program against achondroplasia; an RET-specific inhibitor for lung and thyroid cancer; and FGFR4-specific inhibitor liver and solid tumors. It utilizes SNAP, a proprietary in-house discovery engine to discover and develop molecular structures for cancer. Tyra is headquartered in Carlsbad, California, the US.
The operating loss of the company was US$58.9 million in FY2022, compared to an operating loss of US$26.3 million in FY2021. The net loss of the company was US$55.3 million in FY2022, compared to a net loss of US$26.3 million in FY2021.

For a complete picture of TYRA-300’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.